Been spending way too much time on FSLR and I want to test this thesis before I add more.
Quick numbers at $188:
Market cap ~$20B, net cash $2.3B, 2025 OCF was $2.06B (vs $602M in 2023, so it's tripled), trades around 13x trailing.
The bear case is the loudest take in every thread on this name. Goes like: 100% of 2025 net income comes from Section 45X manufacturing credits, those phase out 2030-2032 under OBBBA, ergo subsidy stock and fairly priced. I bought into this for a while honestly.
What changed my mind is just running through the cash flow.
2026 through 2032 is roughly $13B of cumulative FCF if you assume capex normalizes (it should, Louisiana ramp is basically done, capex guide for 2026 is $0.8-1.0B and probably below $500M by 2027). Add the $2.3B already on the balance sheet and you're at ~$15B of distributable capital against $20B mkt cap.
That's 75% of market cap, in cash, over 7 years. And you still own a profitable manufacturing business at the end of it.
I keep waiting to find what's wrong with this math and I haven't yet, which is making me nervous.
On the "ex-45X earnings are zero" point everyone leans on. Yes technically true if you just back out the credits. But 2025 cost of sales had a bunch of stuff that's clearly transitory:
Louisiana underutilization ~$216M, elevated logistics ~$174M (detention/demurrage), warehousing ~$131M, tariffs on imported modules ~$94M, and a $50M one-time Series 7 warranty hit. So roughly $665M of cost that shouldn't be in a normalized year.
Strip those out, ex-45X pre-tax is closer to ~$650M. Like 12% margin on a normalizing base, not break-even. The bear math is anchoring on peak transitional cost and calling it the run rate, which it isn't.
The other thing the bears miss imo is that 45X isn't propping up a broken business. It's Congress paying the only at-scale non-Chinese solar manufacturer to do exactly what the US government wants (onshore manufacturing). Plus FEOC rules in OBBBA actively lock out the Chinese competitors who'd otherwise undercut them. The credits are aligned with policy, not a band-aid.
Where I get less confident is capital allocation, which is the whole ballgame.
If they buy back $7B at current prices that's ~37M shares retired, around 35% of the float. On normalized post-cliff NI of ~$1.1B with ~70M shares left you get $15+ EPS. At 14x that's $210, at 16x it's $240. And that assumes no margin expansion at all.
More aggressive case (bigger buyback, plus the CuRe/tandem perovskite roadmap actually delivers margin expansion to ~18%) gets you to $25+ EPS in 2033 and $375-450 fair value at 15-18x.
Problem is FSLR has literally never paid a dividend and historically has been pretty conservative on buybacks. So the whole thesis hinges on them changing their behavior, which is not nothing. I'd really like to see a buyback authorization announced before the cash starts piling up because once it's just sitting on the balance sheet earning 4% it's basically value destruction.
Other stuff I'm worried about:
- Demand pull-forward into 2026-2028 as developers race ITC deadlines, then a valley in 2029-2031 right when FSLR needs demand.
- Perovskite tandems from competitors leapfrogging CdTe (their own tandem roadmap is supposed to address this but execution risk is real).
- They build new capacity into peak demand and underutilize it post-cliff. Reinvestment at sub-cost-of-capital.
- Backlog quality. They're sold out through 2028-2029 on paper but a lot of those contracts have termination clauses and ASP renegotiation triggers, so the backlog is softer than the headline number suggests. Negative bookings last quarter is a real signal even if the absolute backlog is still big.
The stock is down ~23% since Q4 print and 2026 guide ($4.9-5.2B) actually shows a revenue decline, so the market is clearly pricing in something bad. I just can't square that with the cash generation profile if you take a 5+ year view.
My honest read: this looks like a setup where you're paying ~13x for a 7-year cash harvest that returns most of the market cap, with a still-profitable business at the end and a regulatory moat against Chinese competition. The risk isn't that it goes to zero. The risk is dead money for a year or two while the market waits for management to commit to capital return.
Am I missing something obvious here? Specifically interested if anyone has dug into the backlog quality / termination clause stuff or has a view on whether the tandem roadmap is real.
Long, ~3% position, considering adding.